GlaxoSmithKline

Report: Drug discovery industry must embrace open source innovation to speed process, boost bottom lines

Monday, January 3, 2011 07:30 AM

To meet the challenges of research and development, the pharmaceutical industry must adopt more open source innovation—a concept that has been used for nearly three decades by the information technology sector—to promote innovation in the drug discovery process and boost bottom lines, according to a new report by Frost & Sullivan.

More... »

ProPublica report: big pharma paid hundreds of physicians over $100,000 in speaking fees

Monday, November 8, 2010 11:12 AM

Several doctors paid to speak on behalf of big pharmaceutical companies aren’t, in fact, the thought leaders consumers often consider them to be, but instead have been sanctioned for various forms of misconduct. And psychiatrists collect more in speaking and consulting fees from pharma companies than doctors in any other specialty.

More... »

More big pharmaceuticals join trend of partnering with CROs to cut costs, speed drug development

Monday, October 11, 2010 10:27 AM

Major pharmaceutical companies are increasingly forming long-term, strategic partnerships with a small number of global contract research organizations (CROs) in order to cut costs and streamline their outsourced clinical work.

More... »

Aptuit Acquires GlaxoSmithKline’s Research
Operations in Italy

Tuesday, July 13, 2010 08:15 AM

Global pharmaceutical services company Aptuit has acquired GlaxoSmithKline’s Medicines Research Center, the largest R&D facility in Italy, in a deal that assures continued employment for nearly 500 staff members at the site.

More... »

CenterWatch Monthly May 2010

Tuesday, May 4, 2010 12:51 PM

Euro Sites Rate Abbott, Boehringer Ingelheim Top Sponsors in 2010

More... »

Clinical Trial Activity in Russia Dipped in 2009

Friday, March 5, 2010 06:56 AM

According to Russia-based contract research organization (CRO) Synergy Research Group’s Annual Orange Report, Russia’s regulatory agency Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (RosZdravNadzor, RZN) approved 577 new clinical trials during 2009, 6% fewer than in 2008. Sixty percent, or 348 of the new studies, were multinational multi-center trials, down 4% from 2008.

More... »

UBC Opens First Office in Asia-Pac

Monday, February 15, 2010 04:51 PM

United BioSource Corporation’s (UBC’s) new office in Tokyo, Japan, is the company’s first office in that country and in all of Asia-Pacific.

More... »

Lindevall Returns as CEO of Encorium

Friday, January 15, 2010 06:44 AM

CEO musical chairs continues at Wayne, Pa.-based contract research organization (CRO) Encorium . The company has reappointed Dr. Kai Lindevall as CEO, replacing David Ginsberg who left the company last summer when Encorium sold its U.S. business to Pierrel Research USA and Ginsberg became CEO there. Ginsberg had replaced Lindevall as CEO in September 2008. Lindevall, who replaced Kenneth Borow, M.D., as CEO in February 2008, has served as executive chairman since Ginsberg became CEO. Board member Shahab Fatheazam will serve as Encorium’s new chairman.  

More... »

GSK, US Oncology in Clinical Trial Alliance

Monday, October 26, 2009 06:47 AM

The Oncology R&D unit of GlaxoSmithKline (GSK) has entered into a new research alliance agreement with US Oncology, a nationwide cancer care company that supports a community-based research network specializing in phase I through IV oncology clinical trials. The non-exclusive collaboration is aimed at improving the execution time of GSK’s oncology clinical trials.

More... »

Ecron Acunova Founder Steps Down

Friday, April 24, 2009 08:29 AM

Ecron Acunova, a CRO based out of Germany, India and the United States, appointed Antal Hajos managing director and CEO Europe, replacing ECRON founder and CEO Klaus Wiedey, who will serve as an advisor to the company. In his new role, Hajos will oversee all business, strategic and operational aspects of the European operations. Prior to joining Ecron Acunova last year, Hajos was director of global clinical operations with Altana Pharma and later CEO of Altana/Nycomed’s research and development center and Indian affiliate in Mumbai, India.

More... »